Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Krupi Parmar"'
Autor:
Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, for the PRESS XII study group, Deven Parmar
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-13 (2020)
Abstract Background The potential for PPAR agonists to positively affect risk of cardiovascular disease in patients with type 2 diabetes (T2DM) is of persistent attention. The PRESS XII study primarily aimed to evaluate the efficacy and safety of sar
Externí odkaz:
https://doaj.org/article/bc36f5900d644e158456c59a7de79a28
Autor:
Upendra Kaul, Deven Parmar, K. Manjunath, Mitesh Shah, Krupi Parmar, Kishor P. Patil, Ashok Jaiswal
Publikováno v:
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-11 (2019)
Abstract Background Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-α and γ agonist actions, respectively. It was g
Externí odkaz:
https://doaj.org/article/9508855dcccb48848a4574ebb99f98f4
Publikováno v:
Acta Diabetologica. 57:809-818
Lowering postprandial lipemia may mitigate cardiovascular risk in patients with diabetic dyslipidemia. This study was aimed to investigate whether saroglitazar suppresses postprandial lipemia in patients with diabetes and dyslipidemia. This was a 12-
Autor:
Ashu, Rastogi, Richard L, Dunbar, Hemant P, Thacker, Jayesh, Bhatt, Krupi, Parmar, Deven V, Parmar
Publikováno v:
Acta diabetologica. 57(7)
Lowering postprandial lipemia may mitigate cardiovascular risk in patients with diabetic dyslipidemia. This study was aimed to investigate whether saroglitazar suppresses postprandial lipemia in patients with diabetes and dyslipidemia.This was a 12-w
Autor:
Chintan Y. Shah, Maulik R. Patel, Rahul J. Gupta, Raghav Sukhadiya, Deven Parmar, Heather Heading, Mukul R. Jain, Devang P. Parikh, Kinjal Barot, Harilal Patel, Hardik B. Patel, Nuggehally R. Srinivas, Vyom N. Dholakia, Kevinkumar Kansagra, Rajendrakumar H. Jani, Krupi Parmar, Jason Lickliter
Publikováno v:
Clinical Pharmacokinetics
This phase I study of ZYAN1 was conducted to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. The study was a randomized, double-blind, placebo-controlled phase I study carried out in two pa
Autor:
Mitesh Shah, Ashok Jaiswal, Nungshijungla, Upendra Kaul, Priyadarshini Arambam, Vineet Bhatia, Ranjan Kachru, Krupi Parmar, Yumnam Diana, Peeyush Jain
Publikováno v:
Journal of Diabetes & Metabolism. 10
Objective: Diabetic dyslipidemia is highly atherogenic as it is associated with high triglyceride (TG), high small dense low-density lipoprotein (sd-LDL) particles and low high-density lipoprotein cholesterol (HDL-C). Saroglitazar, a dual peroxisome
Autor:
Krupi Parmar, Kevinkumar Kansagra, Devang P. Parikh, Hardik B. Patel, Maulik R. Patel, Harilal Patel, Jaimik A. Patel, Uday S. Patil, Deven Parmar, Nuggehally R. Srinivas, Mayur M. Soni, Swagat S. Gujarathi
Publikováno v:
Clinical drug investigation. 38(1)
Peroxisome proliferator-activated receptors (PPARs) have recently become a focus of interest for their important roles in glucose and lipid metabolism. In humans, PPARα activation causes a decrease in plasma triglyceride (TG) levels, enhancement of